Hill, L., Clements, M., Turner, M., Dona, D., Lutsar, I., Jacqz-Aigrain, E., . . . Sharland, M. (2021). Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): A multicentre, randomised, open-label, phase 2b, non-inferiority trial. Elsevier.
Lua i Stíl Chicago (17ú heag.)Hill, L., et al. Optimised Versus Standard Dosing of Vancomycin in Infants with Gram-positive Sepsis (NeoVanc): A Multicentre, Randomised, Open-label, Phase 2b, Non-inferiority Trial. Elsevier, 2021.
Lua MLA (9ú heag.)Hill, L., et al. Optimised Versus Standard Dosing of Vancomycin in Infants with Gram-positive Sepsis (NeoVanc): A Multicentre, Randomised, Open-label, Phase 2b, Non-inferiority Trial. Elsevier, 2021.
Rabhadh: Seans nach mbeach na luanna seo go hiomlán cruinn i ngach uile chás.